Effect of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Plasma Insulin Levels
NCT ID: NCT06597149
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-04-16
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigators hope that by stimulating the vagal nerve using the TeNS behind the ear, this stimulation can affect insulin levels, and this will help innovate treatment of patients with nausea, vomiting, and disordered stomach function, and patients with diabetes.
Researchers hope to be able to measure the activity of the vagus nerve when it is stimulated in other ways. This could help investigators learn more about studying this nerve in the future.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary: The research described in this protocol is best described as an extension of the researcher's current protocol which is designed to measure cervical compound vagal nerve action potentials in patients who have an implanted gastric electrical stimulation device (GESD). The difference is that only healthy volunteer subjects will be recruited and studied, and rather than undergoing gastric electrical stimulation (GES), volunteer subjects will undergo transcutaneous stimulation of the auricular branch of the vagus nerve (taVNS) to determine whether this modality will also influence plasma insulin, C-peptide and glucose levels. While not a part of the current proposal; if the results of this study are promising we anticipate applying electrical stimulation of the ABVN in future studies of gastroparetic patients with symptomatic nausea and vomiting.
Secondary/exploratory: If taVNS proves to have an effect on circulating plasma insulin levels, then a secondary component of this study is to determine which subject variables (age, gender, BMI) may influence this response. While not formally a part of this proposal, investigators anticipate future studies will be designed to determine the optimal stimulus parameters (stimulus current, frequency, pulse duration) needed to produce this effect. Researchers' previous investigation using percutaneous electrical nerve field stimulation (PENFS) have shown that this modality affects the sympathetic and parasympathetic controls or heart rate variability. The current proposal will also determine whether the same effect occurs with transcutaneous auricular vagus nerve stimulation (taVNS).
SPECIFIC AIM 1:
To determine if acute taVNS stimulation of the cymba concha area of the external ear in human subjects affects plasma insulin, C-peptide, and glucose levels.
Investigators' preliminary studies show that electrical stimuli applied to electrodes implanted in the serosa of the stomach augment plasma insulin levels in humans. Presumably this is due activation of sympathetic and parasympathetic nerves which also innervate the pancreas. Researchers propose to non-invasively access the vagus nerve by applying electrical stimuli to the cymba concha area of the human external ear. This area is innervated by the cutaneous branch of the vagus nerve which, in turn, sends branches to the sensory nucleus of the vagus nerve, the nucleus tractus solitarius, which then sends nerve fibers throughout the brainstem to control autonomic function throughout the autonomic nervous system.
SPECIFIC AIM 2:
To determine if acute taVNS of the cymba concha area of the external ear affects heart rate variability in human subjects.
Heart rate variability is governed by parasympathetic and sympathetic nerves. By using frequency-domain and time domain analysis it is possible to determine whether 1) taVNS activates the auricular branch of the vagus nerve, and 2) whether any observed effects are mediated through the parasympathetic and/or sympathetic autonomic nervous system.
SPECIFIC AIM 3:
To determine if the changes in plasma insulin, C-peptide, or glucose levels are associated with corresponding changes in parasympathetic or sympathetic activation.
By using frequency-domain and time-domain analysis of heart rate variability it is possible to determine whether any observed changes are due to activation of parasympathetic or sympathetic nervous system or a combination of both. Some subjects may show a greater change in plasma insulin, C-peptide or glucose levels than others during taVNS. Researchers propose to determine whether these changes are mirrored by corresponding alterations in parasympathetic and sympathetic nervous system activity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stimulation
Subjects are placed supine, ECG electrodes are applied, a butterfly catheter is inserted into a peripheral vein. A 5 ml sample of blood is withdrawn. A TENS device is placed on the cutaneous branch of the auricular branch of the vagus nerve. After a twenty-minute baseline reading, the TENS unit is then turned ON and electrical stimuli are delivered over 40 minutes. A second sample of blood representing the experimental period is drawn at the end of the 40 minutes. The TENS device is then turned to the OFF positon and after twenty minutes a third and final sample of blood is drawn.
Transcutaneous Auricular Vagus Nerve Stimulation
Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcutaneous Auricular Vagus Nerve Stimulation
Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-70
* Willing to have ECG electrodes placed on their neck and chest areas.
* Willing to have electrodes placed in the external ear.
* Willing to have an indwelling catheter placed to avoid multiple sticks for blood draw.
Exclusion Criteria
* Diabetes diagnosis per patient report
* Having known allergies to adhesive on electrode pads or bandages
* Self -report of diagnosis of gastric motility issues
* Taking any medications that may affect gastric motility or cardiac variability, i.e. alpha or beta blockers for hypertension.
* Pregnant females
* Those unwilling to have the taVNS device placed in their ear.
* Those unwilling to consent to a blood draw.
* Prisoners
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas V. Nowak
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas V Nowak, MD
Role: PRINCIPAL_INVESTIGATOR
IU Medical Scool
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University Hospital
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maureen Schilling, BS
Role: primary
Thomas V Nowak, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):38-42. doi: 10.1055/s-2004-830525.
Huang F, Dong J, Kong J, Wang H, Meng H, Spaeth RB, Camhi S, Liao X, Li X, Zhai X, Li S, Zhu B, Rong P. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study. BMC Complement Altern Med. 2014 Jun 26;14:203. doi: 10.1186/1472-6882-14-203.
Vosseler A, Zhao D, Fritsche L, Lehmann R, Kantartzis K, Small DM, Peter A, Haring HU, Birkenfeld AL, Fritsche A, Wagner R, Preissl H, Kullmann S, Heni M. No modulation of postprandial metabolism by transcutaneous auricular vagus nerve stimulation: a cross-over study in 15 healthy men. Sci Rep. 2020 Nov 24;10(1):20466. doi: 10.1038/s41598-020-77430-2.
Kozorosky EM, Lee CH, Lee JG, Nunez Martinez V, Padayachee LE, Stauss HM. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022 Apr;10(8):e15253. doi: 10.14814/phy2.15253.
Yin J, Ji F, Gharibani P, Chen JD. Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes. Obes Surg. 2019 Sep;29(9):2869-2877. doi: 10.1007/s11695-019-03901-9.
Payne SC, Ward G, Fallon JB, Hyakumura T, Prins JB, Andrikopoulos S, MacIsaac RJ, Villalobos J. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol Rep. 2022 Apr;10(8):e15257. doi: 10.14814/phy2.15257.
Hampton RF, Jimenez-Gonzalez M, Stanley SA. Unravelling innervation of pancreatic islets. Diabetologia. 2022 Jul;65(7):1069-1084. doi: 10.1007/s00125-022-05691-9. Epub 2022 Mar 29.
Zhu Y, Xu F, Lu D, Rong P, Cheng J, Li M, Gong Y, Sun C, Wei W, Lin L, Chen JDZ. Transcutaneous auricular vagal nerve stimulation improves functional dyspepsia by enhancing vagal efferent activity. Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G700-G711. doi: 10.1152/ajpgi.00426.2020. Epub 2021 Feb 24.
Krasaelap A, Sood MR, Li BUK, Unteutsch R, Yan K, Nugent M, Simpson P, Kovacic K. Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2020 Aug;18(9):1987-1994.e2. doi: 10.1016/j.cgh.2019.10.012. Epub 2019 Oct 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24300
Identifier Type: -
Identifier Source: org_study_id